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Abstract
Signaling by lipopolysaccharide (LPS) through CD14 involves the activation of protein tyrosine kinases of the src family
and leads to cytokine production and activation of arachidonic acid metabolism in macrophages. CD45 protein tyrosine
phosphatase (PTPase) might play a role in modulating the response through this pathway. Although a critical role in
regulation of T-cell signaling for CD45 has been demonstrated, little is known about its role in macrophages. Monoclonal
antibodies to CD45 and F(abP)2 fragments of the monoclonal antibody enhanced the response of differentiated THP-1
monocytic cells to LPS for the release of radiolabeled arachidonic acid metabolites, prostaglandin E2, and tumor necrosis
factor K. The enhancing effect of anti-CD45 mAbs was shown to occur primarily through CD14-dependent signaling by
performing the experiments under conditions favoring that pathway. Further, LPS may be able to alter the enzymatic activity
of CD45, as shown by Western blots of CD45 immunoprecipitates in which LPS caused a transient change in the
phosphorylation state of CD45. We conclude that CD45 appears to play a role in LPS-induced responses through the CD14
pathway, possibly through its PTPase activity. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Considerable evidence has accumulated that mac-
rophage activation by LPS occurs via a receptor
complex consisting of a receptor (CD14) and associ-
ated tyrosine kinases of the src family [1^4]. Signal-
ing through CD14 has several similarities to the sig-
naling through T-cell and B-cell receptors, including
the lack of a cytosolic signaling domain on the re-
ceptor, activation of protein tyrosine kinases of the
src family, and proliferation of multiple signals. The
initial dramatic increase in tyrosine phosphorylation
is transient [5], which suggests that a regulatory
mechanism removes the phosphate groups. It seems
likely that this would be a protein tyrosine phospha-
tase (PTPase) activity.
CD45, the leukocyte common antigen, is a trans-
membrane protein tyrosine phosphatase (PTPase)
which plays a major role in signal transduction in
T cells, B cells, natural killer cells, and neutrophils
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[6^9]. It is the most abundant and well characterized
of the family of transmembrane protein tyrosine
phosphatases in hematopoietic cells [10]. The mole-
cule consists of three domains: a large, extensively-
glycosylated extracellular N-terminal domain, a sin-
gle transmembrane domain, and a cytosolic C-termi-
nal domain that contains two protein tyrosine phos-
phatase activities [11,12] Alternative splicing of
variable exons encoding portions of the extracellular
domain leads to expression of several isoforms of
CD45. These range in molecular mass from 180^
240 kDa, and their expression is tightly regulated
during development and activation of lymphocytes
[13]. Monoclonal antibodies have been developed to
explore the functional relationships of these isoforms
on T cells, and two of them recognize a high molec-
ular mass isoform (CD45RA) and low molecular
mass isoform (CD45RO), respectively. Although
found on monocytes and macrophages, CD45 has
primarily been studied in lymphocytes. Such studies
have demonstrated that CD45 is part of the receptor
complexes on T and B cells, in which its major sub-
strates for dephosphorylation appear to be protein
tyrosine kinases (PTK) [9,14,15]. This suggests that
CD45 has a regulatory role in proximal signal trans-
duction by modulating the phosphorylation^dephos-
phorylation equilibrium, coupling speci¢c surface re-
ceptors to downstream tyrosine kinase-dependent
signaling. It is involved in both positive and negative
regulation depending on whether the particular ki-
nase substrate has phosphorylated tyrosines at inhib-
itory sites or activation sites [13].
Studies regarding the roles of CD45 in monocytes
and macrophages are much more limited. CD45 ex-
pression has recently been shown to be upregulated
on activated epithelium-lining macrophages [16], and
C5a-activated monocytes [17]. There is some evi-
dence for CD45 involvement in monocyte adherence
[18], in synergizing with LPS in triggering M-CSF
production [19] and respiratory burst from mono-
cytes [8], and in regulation of FcQ receptor-induced
calcium mobilization [20,21]. Thus, it is clear that
CD45 may be involved in several aspects of macro-
phage activation. However, very little is known
about the role of CD45 in the activation of macro-
phages by LPS and the signal transduction pathways
involved. The expression and functional importance
of CD45 isoforms on monocytes and macrophages
remain unexplored, and the ligands for binding are
unknown. Since activation by LPS via CD14 results
in tyrosine phosphorylation [1], this pathway is most
likely regulated by a protein tyrosine phosphatase. In
addition, although tyrosine phosphorylation has
been associated with eicosanoid biosynthesis in mac-
rophages [22], there have been no studies linking
CD45 to the regulation of arachidonic acid (AA)
metabolism, another important result of macrophage
activation and a common assay for phospholipase A2
activity.
The major objective of this study was to determine
whether or not the CD45 protein tyrosine phospha-
tase plays a role in the activation of arachidonic acid
metabolism by LPS in THP-1 human monocytic
cells. The hypothesis was based on the role of
CD45 in T cells and the apparent similarity between
that signaling system and the one used by LPS via
CD14, including the evidence of a receptor complex,
activation of tyrosine kinases, and the transient na-
ture of the tyrosine phosphorylation induced by li-
gand binding. Anti-CD45 monoclonal antibodies
(mAb) to CD45 were used to explore expression of
CD45 on THP-1 cells, to measure their e¡ect on
activation of AA metabolism by binding surface
CD45, to correlate these e¡ects with signaling
through the CD14 pathway, and to demonstrate a
possible link between LPS and the enzymatic activity
of CD45.
2. Materials and methods
2.1. Materials
THP-1 cells were purchased from American Type
Culture Collection (Rockville, MD). Balb/C and
Swiss Webster mice were obtained from Jackson
Laboratories. Cellgro RPMI1640 was from Medi-
atech (Herndon, VA), and de¢ned fetal bovine serum
(FBS) was purchased from HyClone (Logan, UT).
Puri¢ed LPS R595 from Salmonella minnesota,
monophosphoryl lipid A (MLA), and diphosphoryl
lipid A (DPL) were provided by Ribi Immunochem
Research (Hamilton, MT). Tritiated arachidonic acid
was purchased from American Radiolabeled Chem-
ical Co. (St. Louis, MO). Vitamin D3 (1K,25-dihy-
droxyvitamin D) was purchased from Calbiochem
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(La Jolla, CA). Anti-CD45 clone 2D1, anti-
CD45RA, anti-CD45RO, and Mq-P9 anti-CD14/
FITC monoclonal antibodies and isotype-matched
negative controls were from Becton^Dickinson Im-
munocytometry Systems. Dr. Ken Davis of Becton^
Dickinson kindly provided F(abP)2 fragments (Mr 94
kDa) of anti-CD45 mAb, clone 2D1. Anti-mouse
anti-CD45 monoclonal antibodies (HI-30) were
from Pharmingen (San Diego, CA). Enzyme Immu-
noassay kits for eicosanoids were obtained from
Cayman Chemical Co. (Ann Arbor, MI), and those
for TNFK were from R p D Systems (Minneapolis,
MN). Anti-CD14 UCHM-1, isotype-matched control
antibodies (IgG2a), and all other chemicals were pur-
chased from Sigma Chemical Co. (St. Louis, MO).
2.2. Cell culture
THP-1 cells were grown in RPMI supplemented
with 10% FBS, 100 U penicillin, 0.1 mg/ml strepto-
mycin, and 2 mM L-glutamine, and maintained be-
tween 2U105 and 6U105 cells/ml at 37‡C with 5%
CO2. Viability remained above 97% (by trypan blue
exclusion) throughout the experiments. THP-1 cells
were pretreated for 24 h with 0.1 WM vitamin D3 to
induce expression of CD14, the putative LPS recep-
tor and marker for a more mature (macrophage)
phenotype. Murine peritoneal macrophages (PEC)
were harvested from Balb/c mice by peritoneal lavage
using 10 ml RPMI injected into the peritoneal cavity.
PECs were plated to 24-well plates and, after a 2-h
adherence period, nonadherent cells were washed o¡
and fresh medium was added. They were then labeled
with [3H]arachidonic acid at 0.25 WCi/ml overnight.
2.3. Cell activation
Prior to challenge the THP-1 cells were washed
with warm RPMI, resuspended in 25 ml of RPMI,
and transferred to 24-well culture plates (1 ml/well).
The ¢nal heat-inactivated serum concentration was
2.5^5%, and ¢nal cell densities were in the range 5^
8U105 cells/ml. LPS was solubilized in 0.1% triethyl-
amine in a 100 mg/ml stock solution. Monoclonal
antibodies were titered for use at approximately
1 Wg/ml for 106 cells, and diluted in RPMI. Iso-
type-matched mAb were used to rule out nonspeci¢c
e¡ects and of binding by FcR on the macrophages.
Endotoxin levels of vitamin D3 and media solutions
were shown to be below detectable levels by Limulus
assay. Isotype control antibody preparations also
containing azide served as controls for e¡ects on re-
sponse.
At the end of challenge time periods, samples were
removed from the wells, cells were pelleted by cen-
trifugation, and 200 Wl of the supernatant were
counted in a Beckman scintillation counter to deter-
mine the amount of radiolabeled arachidonic acid
metabolites released. Supernatants were also assayed
for prostaglandin E2, leukotrienes C4 and B4, and
TNFK using EIA kits, following manufacturers’ in-
structions (Cayman and R p D Systems).
2.4. Flow cytometry
After overnight treatment with LPS R595 or
MLA, D3-pretreated THP-1 cells were stained with
FITC or phycoerythrin (PE) conjugated monoclonal
antibodies to CD45, CD45RA, and CD45RO from
Becton^Dickinson. The staining period was 30 min
at 4‡C. Cells were washed twice with staining bu¡er
(PBS, 0.05% sodium azide, 2% FBS) and ¢xed with
1% bu¡ered paraformaldehyde. PE and FITC con-
jugated isotype-matched negative control myeloma
proteins were used throughout to quantitate nonspe-
ci¢c background binding to target cells. Forward
angle (FALS) and 90‡ (orthogonal) light scatter gat-
ing eliminated debris and dead cells from the analysis
on a Coulter Elite £ow cytometer. Data represent the
percentage of positively stained cells for a given anti-
body, projected beyond the cursors set on negative
control histograms to separate positively and nega-
tively stained cells. Cursors were set so that 1^2% of
all cells stained with the negative control, isotype-
matched reagents were displayed as being in the pos-
itive region of the histogram.
2.5. SDS^PAGE and Western blotting
D3-Pretreated THP-1 cells (1U107) were lysed in
1 ml lysis bu¡er for 1 h at 4‡C. (Lysis bu¡er: 1%
Triton X-100, 20 mM Tris^HCl (pH 7.4), 137 mM
NaCl, 2 mM EDTA, 1 mM phenylmethylsulfonyl-
£uoride (PMSF), 1 Wg/ml each of pepstatin, aproti-
nin and leupeptin, 1 mM sodium orthovanadate
(NaVO4), and 100 WM Phenylarsine oxide (PhAsO).)
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The lysate was pelleted at 10 000Ug for 30 min, and
supernatants were transferred to fresh tubes. For im-
munoprecipitation, 20 Wl of anti-CD45 was added
and incubated for 2 h at 4‡C. 50 Wl of protein-G
sepharose was then added and incubated at 4‡C
overnight on an inverter shaker. Precipitate was
washed twice in lysis bu¡er, and once in wash bu¡er
(50 mM Tris^HCl (pH 7.4), 200 WM NaVO4, 100 WM
PhAsO). Samples were boiled in sodium dodecyl sul-
fate^polyacrylamide gel electrophoresis (SDS^
PAGE) sample bu¡er for 5 min prior to loading
onto 7.5% SDS^PAGE gels. Gels were run in a Bio-
Rad Minigel apparatus for 40^60 min, then blotted
onto PDVF membranes. Blots were stained with bio-
tinylated anti-phosphotyrosine antibodies (Sigma). A
molecular mass standard containing myosin at 202
kDa was used routinely as an internal control, and it
was found that this band stained with the anti-PY
mAb and was therefore left as the molecular mass
marker in the immunoblots. Blots were then treated
for 1 h at room temperature in blocking bu¡er with
streptavidin/horseradish peroxidase, then washed
three times. Blots were developed and ¢lms exposed
using enhanced chemiluminescence (ECL) kits from
Amersham.
2.6. Statistical analysis
Experiments were performed with duplicate or
triplicate samples, using multiple concentrations as
the variable treatments. Statistical variance (P)
among treatment sets was determined by one-way
ANOVA test or Tukey test using the SigmaStat sta-
tistics program.
3. Results
3.1. THP-1 cells express CD45 constitutively without
change in relative expression of CD45RO and
CD45RA after LPS treatment
Because the functional importance of CD45 iso-
forms on macrophages is not known, commercially
available anti-CD45 mAbs to known isoforms were
used. Due to the conserved nature of the phospha-
tase domains, it was assumed that maximum binding
would give maximum response. It was also necessary
to be sure that treatment with LPS would not a¡ect
the expression of CD45, thus complicating the chal-
lenge results. Fig. 1 shows £ow cytometric histo-
Fig. 1. Treatment with LPS or MLA did not a¡ect CD45 isoform expression on THP-1 cells. D3-Pretreated THP-1 cells were treated
with medium alone (A,B), LPS (100 ng/ml; C,D), or MLA (1 Wg/ml; E,F) and then stained with PE-labeled 2D1 anti-CD45 (B,D,F)
or PE-labeled isotype control IgG1/IgG2a (A,C,E). The stained cells were analyzed by £ow cytometry as described in Section 2. These
results are from a single representative experiment. The same results were obtained from two additional experiments.
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grams for staining with anti-CD45 2D1 which recog-
nizes all known T-cell isoforms (pan CD45 mAb).
The cursors were set on IgG1/IgG2a negative control
histograms so that only a small percentage (0.1^
1.6%) of the cells staining with the negative control
antibodies were counted as positive. Neither LPS nor
MLA altered the expression of this epitope in three
separate experiments, of which Fig. 1 is representa-
tive. Table 1shows the results of £ow cytometric
analysis of THP-1 cells stained with mAb to 2D1
and two of the major isoforms of CD45 expressed
on leukocytes. Although 63% of the cells expressed
CD45RA, there appear to be signi¢cantly fewer mol-
ecules expressed per cell than CD45RO, as shown by
the mean £uorescence of 0.699. 95.7% of the cells
stained positive for anti-CD45 clone 2D1 at a mean
£uorescence of 9.52. This pattern did not change
signi¢cantly following treatment with LPS (R595)
or MLA, suggesting that activation of macrophages
by these agents does not alter expression of these
CD45 isoforms. Anti-CD45 2D1 was used for subse-
quent challenge experiments.
3.2. Anti-CD45 mAb increased the release of
labeled arachidonic acid metabolites from
LPS-challenged cells
Addition of anti-CD45 2D1 18 h prior to challenge
caused a 2-fold increase over the amount of 3H re-
leased from cells challenged only with LPS (Fig. 2).
Although an e¡ect of anti-CD45 during challenge
elicited an e¡ect during initial studies, subsequent
experiments consistently showed that pretreatment
yielded more consistent and signi¢cant increases.
Similar results were seen when mouse peritoneal cells
(PECs) were treated with anti-mouse KCD45 18 h
prior to challenge (data not shown, P6 0.02 for
[LPS] = 1^1000 ng/ml). Repeating the experiments
with murine peritoneal cells provided a comparison
to demonstrate that the e¡ects were neither species
speci¢c nor restricted to THP-1 cells.
3.3. Production of prostaglandin E2
One of the important eicosanoids released from
LPS-activated macrophages is PGE2 [22,24]. Anti-
CD45 increased production of PGE2 from LPS-chal-
lenged cells (Fig. 3). There was no production of
LTC4 or LTB4 with either LPS, LPS and anti-
CD45, or anti-CD45 alone (data not shown). The
similarity in response in this model for challenge
with LPS and anti-CD45 suggests that, in terms of
prostaglandin and leukotriene production, anti-
Table 1
Surface expression of CD45 isoforms on vitamin D3-pretreated
THP-1 cells following treatment with medium alone, LPS or
MLA, as measured by £ow cytometrya
Treatment
Medium LPS MLA
KCD45RA 63.1b 61.4 53.9
0.699c 0.6 0.557
KCD45RO 24.5 27.4 25.2
3.52 3.43 3.64
KCD45 (pan) 95.7 97.1 97.8
9.52 14.2 11.2
aTHP-1 cells were treated for 18 h with medium only, 100 ng/
ml LPS R595, or 1000 ng/ml MLA. Cells were then stained
and analyzed by £ow cytometry as described in Section 2.
bPercent of gated (90‡ vs. FALS) cells staining positive.
cMean channel £uorescence - 4 decade logarithmic range.
Fig. 2. Anti-CD45 mAb increased [3H]arachidonic acid release
from LPS-challenged THP-1 cells. D3-Pretreated THP-1 cells
were labeled overnight with 0.5 WCi/ml [3H]AA and then
washed, resuspended in RPMI with 5% FBS, and plated in 24-
well plates at 1.5U106 cells/ml. Anti-CD45 2D1 (1 Wg/ml) was
added 18 h prior to challenge, during the labeling period. The
cells were challenged with LPS R595 at concentrations shown
for 3 h. Supernatants were centrifuged to remove cells, and 200
Wl of cell-free supernatant were counted in a Beckman scintilla-
tion counter. Values represent cpm released from 3U105 cells
above control values for cells challenged with medium alone,
and are averages of duplicates þ (range). Statistical variance
across all concentrations compared to control, P6 0.001. For
each concentration, statistical variance between treatment
groups, *P6 0.02.
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CD45 simply increased the signal generated by LPS,
but did not change which signaling pathways were
activated.
3.4. Enhancement of LPS activation did not appear to
involve Fc receptor (FcR)
Macrophages express Fc receptors (FcR) for bind-
ing particles opsonized with antibodies. Binding of
FcR can lead to activation of several pathways
[20,23]. To determine whether FcR activation was a
factor in the increased arachidonic acid release,
THP-1 cells were challenged with LPS following in-
cubation with isotype-matched control mAb instead
of anti-CD45. The isotype-matched negative control
IgG1 also had no e¡ect on LPS challenge (Fig. 4A).
We also used mouse serum at 10 Wl/106 cells to £ood
Fc receptors on the macrophages prior to addition of
anti-CD45 mAb to prevent binding of the mAb to
FcR. The pattern of enhancement seen in Fig. 2 was
consistent in the presence of mouse serum (data not
shown). Finally, F(ab)2 fragments of anti-CD45
mAb, clone 2D1 (at approximately 2/3 the concen-
tration used for whole antibody) were used to mea-
sure their e¡ect on challenge with LPS. There was a
statistically signi¢cant increase in the release of ara-
chidonic acid (data not shown; P6 0.05 at all con-
centrations) and PGE2 (P6 0.01) (Fig. 4B) using
these fragments.
3.5. Production of TNFK
To determine whether anti-CD45 also a¡ected sig-
naling pathways for proin£ammatory cytokines,
supernatants from LPS-treated cells were assayed
for TNFK. Fig. 5 shows that anti-CD45 enhanced
the release of this pro-in£ammatory cytokine at all
LPS concentrations above that released by LPS
Fig. 3. Anti-CD45 increased PGE2 released from LPS-chal-
lenged cells. Samples from Fig. 2 were assayed for PGE2 using
EIA (Cayman), following manufacturer’s instructions. PGE2 in
pg/ml was calculated from a standard curve. Values are pg/ml
released above control, and are averages of duplicates. Two
subsequent experiments showed similar results.
Fig. 4. (A) Isotype-matched control antibodies had no e¡ect on
AA release. D3-Pretreated THP-1 cells were labeled overnight
with 0.5 WCi/ml [3H]AA, then washed and plated in 24-well
plates at 5U105 cells/ml. LPS (1 Wg/ml) or 1 Wg/ml of the vari-
ous antibodies were added to wells 18 h prior to challenge. The
mAbs used were anti-CD45 clone 2D1 (Becton^Dickinson,
IgG1), and IgG1 isotype control (Becton^Dickinson). Cells were
challenged for 2 h, then 200 Wl of cell-free supernatants were
counted for cpm released. Values are averages of duplicates þ
(range). *P6 0.01, compared to control. (B) F(abP)2 fragments
enhanced PGE2 release. D3-Pretreated THP-1 cells were treated
for 18 h with F(abP)2 fragments, then challenged for 2 h with
LPS at concentrations shown. Culture supernatants were as-
sayed for PGE2 by EIA (Cayman) according to manufacturer’s
instructions. PGE2 in pg/ml was calculated from a standard
curve. *P6 0.01.
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alone. On repeated experiments, there was consider-
able variability in the amount of TNF released, pre-
cluding statistical analysis between experiments.
However, there was consistent enhancement by
anti-CD45 while the mAb alone had little e¡ect.
3.6. Correlation of the e¡ects of anti-CD45 with
signaling through the CD14 signaling pathway
In order to explore the possibility that the e¡ect of
anti-CD45 was due to alteration of signaling through
the CD14 pathway, a series of experiments was done
under conditions that favored signaling through
CD14. CD14 speci¢cally binds complexes of LPS
and its serum binding protein, LBP. Therefore,
THP-1 cells were challenged in medium without se-
rum to determine the e¡ect of anti-CD45 in the ab-
sence of LBP. No enhancing e¡ect of anti-CD45 was
seen under these conditions (data not shown;
P = 0.7).
Pretreatment of THP-1 cells with vitamin D3 in-
creases CD14 expression by 50^80% [27]. If the en-
hancement by CD45 ligation required CD14, this
e¡ect might not be seen if the cells were not treated
with vitamin D3. Therefore, e¡ects of the anti-CD45
pretreatment and LPS challenge were compared on
cells that were not pretreated with D3 to those that
were. Anti-CD45 had very little e¡ect except at the
highest LPS concentration (100 ng/ml) without D3
pretreatment (Fig. 6). However, a signi¢cant e¡ect
was seen with cells treated with D3, even at the low-
est concentration of LPS tested (0.1 ng/ml). There-
fore, expression of CD14 had a signi¢cant impact on
the ability of anti-CD45 to enhance the response to
LPS.
In addition to LPS, several bacterial amphiphiles
have been shown to bind CD14, including MLA,
diphosphoryl lipid A (DPL), and lipoteichoic acid
(LTA) [28]. Other agents, including C2 ceramide,
sphingomyelinase, and phorbol myristate acetate
(PMA), activate AA metabolism independent of
CD14 binding. Anti-CD45 signi¢cantly increased re-
lease from cells treated with all of the CD14 ligands
(Fig. 7A), but none of the CD14-independent agents
(Fig. 7B).
Finally, because LPS can induce signaling by
CD14-dependent and independent pathways, a cor-
relation between the CD14 and the observed e¡ects
of anti-CD45 would be strengthened by direct stim-
ulation of CD14 by an mAb that has been shown to
activate, rather than block, signaling. Anti-CD14
mAb UCHM-1 activates signaling through CD14
for nitric oxide [40], and AA release from THP-1
cells (unpublished data), and may serve as an LPS
Fig. 5. Anti-CD45 mAb enhanced release of TNFK from LPS-
challenged THP-1 cells. D3-Pretreated THP-1 cells were chal-
lenged with medium alone or concentrations of LPS as shown
for 5 h. Culture supernatants were assayed for TNFK using
EIA kits (R p D) following manufacturer’s instructions. TNFK
in pg/ml was determined from a standard curve. Values are
averages of duplicates, and the experiment was repeated three
times with similar results.
Fig. 6. Pretreatment with vitamin D3 increased the e¡ect of
anti-CD45 on AA release. Equal volumes of THP-1 cells at
5U105 cells/ml, treated or not treated with vitamin D3, were la-
beled and challenged as in Fig. 2. Values represent cpm released
in 200 Wl of cell-free supernatants above control, and are aver-
ages of duplicates þ range. At each concentration *P6 0.01
comparing antibody plus LPS to LPS alone in each set.
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agonist, directly activating signaling by binding to an
LPS binding site on CD14. Anti-CD45 signi¢cantly
increased AA release from D3-pretreated cells chal-
lenged with anti-CD14 UCHM-1, but not from cells
that were not treated with D3 to induce CD14 ex-
pression (Fig. 8).
3.7. LPS treatment caused increased phosphorylation
of CD45
The phosphorylation of tyrosines on CD45 has
been shown to modify PTPase activity. The terminal
PTPase domain on CD45 appears to be an autode-
phosphorylation activity [17]. In order to determine
whether LPS a¡ected PTPase activity, the phosphor-
ylation of immunoprecipitated CD45 was compared
with and without LPS treatment of the cells, using
anti-phosphotyrosine monoclonal antibodies to stain
immunoblots of CD45 immunoprecipitates from
lysed THP-1 cells. There was an apparent transient
Fig. 8. Vitamin D3 pretreatment increased the sensitivity of
THP-1 cells to challenge with anti-CD14, and to the e¡ect of
anti-CD45. THP-1 cells, D3 treated or untreated, were labeled
as in Fig. 2 and challenged with 1 Wg/ml anti-CD14 (UCHM-
1), with or without anti-CD45 2D1, for 2 h. Challenges with
isotype-matched mAb (IgG2a) are also shown. Values represent
cpm released in 200 Wl of cell-free supernatants above control,
and are averages of duplicates þ range.
Fig. 7. (A) Anti-CD45 a¡ects AA release activated by other
CD14 ligands: MPL, DPL, and LTA. D3 pretreated THP-1
cells were labeled and challenged as in Fig. 2, and challenged
with either medium alone or 1 Wg/ml LPS R595, MLA, DPL,
or LTA (S. faecalis) for 2 h. (B) Anti-CD45 did not a¡ect
[3H]AA release activated by agents using CD14-independent sig-
naling. D3 pretreated THP-1 cells were labeled as in Fig. 2 and
challenged with 50 WM C2 ceramide, 0.5 U/ml sphingomyeli-
nase (SMase), 10 ng/ml LPS (as positive control) for 2 h, or
20 ng/ml TNFK, 30 ng/ml PMA for 5 h. Values represent cpm
released in 200 Wl cell-free supernatants above control (medium
alone), and are averages of duplicates þ range. The experiments
were repeated three times.
Fig. 9. LPS increased phosphorylation of CD45 within 5 min
after treatment. D3-Pretreated THP-1 cells were treated with
LPS for 1, 5, 15, 30, and 45 min (lanes 2^6), and then lysed in
lysis bu¡er containing NaVO4 and PhAsO to inhibit further
PTPase activity. Lysates were immunoprecipitated with KCD45
2D1 as described in Section 2, and run on 7.5% SDS^PAGE
gels. These were then blotted onto PDVF membranes and
stained with biotinylated anti-phosphotyrosine mAb. The immu-
noblots were developed and ¢lms exposed using ECL. Lane 1,
molecular mass standard showing myosin at 202 kDa resolved
with the anti-PY; lane 7, positive PY control.
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increase in the phosphotyrosine stain after 5 min of
incubation with LPS (Fig. 9).
4. Discussion
Studies on T cells provide both indirect (using
mAbs) and direct (using CD45 knock-outs) evidence
of CD45 involvement in regulation of signaling (re-
viewed in [13]). Tyrosine kinases of the src family in
CD45-de¢cient T cells are hyperphosphorylated on
tyrosines at inhibitory sites. This suggests that
CD45 normally activates the kinases by removing
the phosphate groups from these sites. Because this
occurs in resting cells, CD45 apparently serves to
maintain a state of readiness prior to antigen bind-
ing. This also implies that CD45 must be in close
proximity to these substrates in T cells prior to acti-
vation by antigen. This is consistent with our data
showing constitutively high expression of CD45 on
resting macrophages. We were also able to show that
THP-1 cells express three epitopes of CD45 recog-
nized by mAb to known T-cell isoforms, CD45RA,
RO, and a pan marker (2D1). Ratios of expression of
these epitopes did not change following activation
with LPS or MLA. Any alteration of isoform expres-
sion during macrophage activation must be due to
di¡erent changes than those seen on T cells.
Consistent with the model in T cells, tyrosine ki-
nases appear to be the substrates for dephosphoryla-
tion by CD45 in monocytes, and this activity regu-
lates signal transduction [8,20]. Signaling through
CD14 activates tyrosine phosphorylation [1], and ty-
rosine phosphorylation activated by LPS via CD14 is
associated with release of arachidonic acid metabo-
lites [22] and cytokines [2]. This suggests the possi-
bility that signaling by LPS through CD14 activates
arachidonic acid metabolism via a tyrosine kinase
signaling cascade. The results reported here provide
evidence that CD45 protein tyrosine phosphatase
plays a role in regulating that pathway as well as
the pathway for TNFK. As suggested in the T-cell
model, CD45 may simply maintain a state of read-
iness by keeping tyrosine kinases from being
phosphorylated at inhibitory sites. This is supported
by the fact that addition of anti-CD45 18 h before
challenge had a greater e¡ect than addition just prior
to challenge (Fig. 2; unpublished data), and that
anti-CD45 had little e¡ect by itself (Fig. 4A and
5).
The possibility that some of the e¡ects seen were
due to binding of anti-CD45 to Fc receptors was
considered. However, isotype matched control
mAbs had no e¡ect, and anti-CD45 alone had little
or no e¡ect (Fig. 4). Also, activation by anti-CD45
and LPS led to production of PGE2, but not LTB4
or LTC4, consistent with other studies showing that
LPS only activates cyclo-oxygenase and not 5P-
lipoxygenase [22,24,29], and suggests that anti-
CD45 simply increased signaling by LPS, but did
not activate other pathways. Activation through
FcRQ has been shown to lead to production of
LTB4 from neutrophils and monocytes [25,26]. Fi-
nally, Fc receptor £ooding by mouse serum did not
block the e¡ect of anti-CD45, and F(abP)2 fragments
of anti-CD45 also led to an enhancement of LPS-
induced release of arachidonic acid and PGE2.
Several lines of evidence were used to link the ef-
fects of anti-CD45 with signaling through CD14.
First, it was shown that there was little e¡ect with
Fig. 10. Diagram of possible interactions between CD45 and
LPS-induced signaling. CD45 may interact with LPS/CD14 via
its extracellular domain, and a¡ect tyrosine phosphorylation of
itself and downstream targets via its PTPase activities in the cy-
tosolic domain.
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no serum in the challenge medium. Signaling via
CD14 by LPS requires a serum LPS binding protein,
LBP, for transfer of monomers to CD14 [30,31]. Ab-
sence of LBP reduces cellular sensitivity to LPS, but
LPS can still signal via CD14-independent pathways
[32]. The reduced e¡ect of anti-CD45 in medium
without serum suggests that CD45 may be more ac-
tive in regulating CD14-dependent signaling than
CD14-independent signaling. Similarly, pretreatment
of the cells with vitamin D3, which increases expres-
sion of CD14 also increased the e¡ect of anti-CD45
(Fig. 6). Without D3 pretreatment, anti-CD45 had
almost no e¡ect except at the highest LPS concen-
tration, which would be expected with a low-density
receptor. Finally, other CD14 ligands, including
MLA, DPL, LTA, and an activating mAb to
CD14, also were much more potent for AA release
in the presence of anti-CD45 (Fig. 7A and 8). How-
ever, none of the activating agents that do not bind
CD14 showed this synergistic e¡ect with anti-CD45
(Fig. 7B). The ability of anti-CD14 mAb to induce
signaling has been shown before [40,41]. It suggests
that the speci¢c structure of the ligand for CD14 is
not as important as the ability of bound CD14 to
assemble a functional signaling receptor or transfer
the signal to a secondary receptor. The ability of
anti-CD45 to enhance the response to the anti-
CD14 mAb is strong evidence that the regulatory
e¡ect of CD45 on LPS signaling is CD14-speci¢c,
and makes CD45 a candidate for a co-receptor for
CD14. Fig. 10 is a diagram of a possible CD14/CD45
signaling interaction.
Like the T-cell receptor, CD14 lacks a cytosolic
signaling domain and most likely requires a co-recep-
tor to transduce a signal. The fact that high concen-
trations of LPS can induce signaling independently
of CD14 [32] is further evidence that some other
protein is required for signaling. However, the iden-
tity of that component remains unknown. A require-
ment would be that it could not only a¡ect LPS
signaling, but also interact in some way with LPS.
We have shown that LPS alters the tyrosine phos-
phorylation state of CD45 within minutes of addi-
tion of LPS to the cells. Presumably, this is due to
alteration of the autodephosphorylation activity of
CD45. Although further studies to establish the
mechanism and kinetics of this association are still
under way, these results show that not only can anti-
CD45 a¡ect the outcome of LPS signaling, but that
there is a mechanism by which LPS itself can alter
the dephosphorylation activity of CD45. We are cur-
rently exploring the possibility that phosphorylation
dynamics of CD45 may play a role in LPS-induced
desensitization.
There is evidence in T cells that engagement of the
extracellular domain of CD45 by other glycosylated
cell surface molecules such as adhesion molecules (or
CD45-speci¢c mAbs) can modify the protein tyrosine
phosphatase activity of the cytosolic domain [13].
Based on the T-cell model, our results would suggest
that anti-CD45 increases the protein tyrosine phos-
phatase (PTPase) activity, resulting in an enhanced
responsiveness. Tyrosine phosphorylation has been
correlated with all indices of macrophage activation
studied so far [2,5,21,22,33^35]. Although CD45 ap-
pears to play a role in LPS signaling, the broad range
of pathways a¡ected by CD45 in macrophages [8,17^
21] suggests the possibility that CD45 does not spe-
ci¢cally associate with a single receptor. It may in-
stead a¡ect generalized signaling via src family pro-
tein tyrosine kinases (PTK) by maintaining the
phosphorylation-dephosphorylation equilibrium at a
level that ensures readiness to respond through any
pathways utilizing a PTK cascade. If this is the case,
it may be possible to reduce sensitivity of macro-
phages to multiple signals by inactivating CD45.
Macrophage activation is being studied regarding
its involvement in multiple pathological responses
including septic shock, asthma, stroke, and athero-
sclerosis [36^39]. It is conceivable that treatments or
preventive therapies for these in£ammatory condi-
tions may evolve through the exploration of mecha-
nisms regulating phosphorylation of key enzymes in
signal pathways.
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